Free Daily Podcast Summary
The Bio Report: Daily Summaries Delivered
by Levine Media Group
The Bio Report podcast, hosted by award-winning journalist Daniel Levine, focuses on the intersection of biotechnology with business, science, and policy.
Latest Episodes
The most recent episodes — sign up to get AI-powered summaries of each one.
- 1 weeks ago41 min
Developing an Off-the-Shelf Cell-Based Immunotherapy for Metastatic Breast Cancer
For patients with metastatic breast cancer, successive treatments can lose effectiveness as tumors evolve and resistant cancer cells survive, leaving those who have received multiple therapies with limited options. BriaCell is seeking to address that problem with an experimental, off-the-shelf, cell-based immunotherapy designed to stimulate the immune system against multiple cancer-associated targets rather than a single target. Its lead candidate, Bria-IMT, is being studied in combination with a checkpoint inhibitor in a phase 3 trial, while its next-generation programs aim to offer personalized treatment using off-the-shelf cells. William Williams, CEO of BriaCell, discusses how its therapies work, what earlier clinical findings suggest, and the development path forward.
- 2 weeks ago35 min
A Gut-Level Pivot from Diabetes to a GLP-1 Off-Ramp
GLP-1 medicines have transformed obesity treatment, but what happens when patients stop taking them? For Fractyl Health, the challenge of preventing weight regain has become the focus of its development strategy. The company is advancing Revita, an experimental outpatient procedure designed to regenerate the lining of the duodenum and potentially change how the body regulates weight and blood sugar. Harith Rajagopalan, co-founder and CEO of Fractyl Health, discusses the company’s shift from focusing on type 2 diabetes to maintaining weight loss after patients stop taking GLP-1 medicines, the biology behind its approach, and what it takes to turn the promise of a metabolic reset into a treatment option.
- 3 weeks ago42 min
Targeting Residual Inflammation in Cardiovascular Disease
Cardiovascular disease remains the world's leading cause of death, yet many patients still face substantial risks even after conventional factors such as LDL cholesterol and blood pressure are controlled. Rezera is developing its experimental therapy ruvonoflast, an NLRP3 inhibitor, to address this residual inflammatory risk. The therapy is designed to suppress chronic, tissue-based inflammation while preserving the immune system's ability to respond to infection. Rezera CEO Geoff McDonough discusses the role of inflammation in heart disease, the company’s phase 3 trial of ruvonoflast in peripheral artery disease, and its next-generation, brain-penetrant NLRP3 inhibitor in development for neuroinflammatory conditions.
- Sep 30, 202637 min
Neutralizing Tumor Acidity to Improve Cancer Immunotherapy
Many cancer treatments fail not because immune cells can’t recognize a tumor, but because the hostile environment surrounding it can prevent them from doing their job. Dyve Biosciences is seeking to address that problem by targeting tumor acidity, which the company says can suppress T-cell activity, promote immune evasion, and contribute to resistance to checkpoint inhibitors and other therapies. Its solution is a transdermal drug-delivery platform designed to move a buffering agent through the skin and into systemic circulation. The company’s lead oncology candidate, DYV 800, is intended to raise extracellular tumor pH and thereby make the tumor microenvironment more hospitable to immune attack. Ryan Beal, CEO of Dyve Biosciences, discusses why the company sees acidity as an overlooked but foundational target in oncology, how its delivery technology may overcome the limitations of oral bicarbonate dosing, and indications beyond cancer that the company is pursuing.
- Sep 23, 202626 min
How a Breast-Milk-Derived Peptide Could Change Bladder Cancer Care
For people with non-muscle-invasive bladder cancer, treatment can involve repeated procedures, a high risk of tumor recurrence, toxic therapies and, in some cases, removal of the bladder. Hamlet Biopharma is developing Alpha1H, a synthetic peptide inspired by a protein complex found in human breast milk. Catharina Svanborg, chair of Hamlet Biopharma, discusses how Alpha1H is designed to selectively target bladder tumor cells while sparing healthy tissue, the science that led to the program, and the clinical-development path ahead.
- Sep 16, 202629 min
Targeting Visceral Fat with RNA Therapeutics
GLP-1 therapies have dramatically reshaped obesity care, but the next generation of medicines may be judged by more than how much weight patients lose. A central question is whether treatments can selectively reduce the visceral fat associated with cardiometabolic disease while maintaining the muscle needed for physical function, metabolic health, and durable weight management. Erik Ingelsson, chief scientific officer of Wave Life Sciences, discusses the biology behind a new RNA-based approach designed to remove a natural brake on fat breakdown, how the company is thinking about clinical endpoints and patient populations, and why precision approaches to fat loss could change the definition of success in obesity treatment.
- Sep 9, 202631 min
Engineering T-Cell Engagers for Solid Cancers
T-cell engagers have delivered important advances in blood cancers, but extending their success to solid tumors has proved considerably more difficult. Physical barriers, immunosuppressive tumor microenvironments, and the risk of attacking healthy tissue have constrained the field. Deck Bio is developing multi-target T-cell engagers to address these limitations. Jack Silberstein, the company’s CEO, discusses Deck Bio’s efforts to create therapies that reach more cancer cells, reduce the likelihood that tumors will evade treatment, and minimize harm to healthy tissue.
- Sep 2, 202633 min
Resetting Severe Allergies at Their Cellular Source
For people with severe allergies and mast cell diseases, the risk of a dangerous reaction can shape everyday decisions about food, activities, and family routines. Current treatments generally manage symptoms or lower the likelihood of a reaction, rather than directly targeting the immune cells thought to drive the disease. Allergene AI Therapeutics is developing an in vivo mRNA CAR-T therapy intended to address that underlying biology. The approach aims to temporarily program a patient’s own T cells to target mast cells, with the goal of eliminating sensitized cells and enabling the immune system to rebuild a less reactive mast cell population. Sid Kerkar, founder and CEO of Allergene AI Therapeutics, discusses the scientific rationale for this proposed immune reset, the potential for mRNA and lipid nanoparticle delivery to simplify and broaden access to CAR-T therapy, and the work needed to move the approach from early research into clinical testing.
Get The Bio Report summaries in your inbox
Free AI-powered daily recaps. Key takeaways, quotes, and mentions — in a 5-minute read.
Get Free Summaries →Free forever for up to 3 podcasts. No credit card required.
You Might Also Like
Listeners also like.
Biohack-it
A weekly exploration of biohacking, holistic health, and science-driven strategies for optimizing physical and mental well-being.
The Dr. Hyman Show
Explores root causes of chronic disease and promotes functional medicine, nutrition, and preventive health through expert discussions.
The Pulse
Explores surprising stories in health and science, from operating rooms and labs to breakthrough innovations.
LONGEVITY with Nathalie Niddam
Explores science-backed strategies for extending healthspan through nutrition, biohacking, peptides, and emerging longevity research.
A Shot in the Arm Podcast
Ben Plumley
The Health Continuum
High-performing professionals learn science-based health strategies to sustain energy, focus, and resilience in demanding careers.
The VPZD Show
Two physicians discuss healthcare, medicine, and policy from a contrarian, middle-ground perspective.
Sam Miller Science
Sam Miller
FoundMyFitness
A podcast exploring health, science, nutrition, aging, and fitness.
The Holistic GLP-1 Podcast with Elizabeth McGann
Explores holistic approaches to GLP-1 for metabolic health, weight, and well-being through expert insights and natural strategies.
Health vs Hype with the American Medical Association
A medical expert debunks viral health trends and misinformation with science-backed insights from physicians.
The Dr. Gabrielle Lyon Show
Discusses health, longevity, and mental resilience through science-based conversations with medical and wellness experts.
About The Bio Report
The Bio Report podcast, hosted by award-winning journalist Daniel Levine, focuses on the intersection of biotechnology with business, science, and policy.
Customized Recaps
AI-powered recaps with compact key takeaways, quotes, and insights.
Straight to Your Inbox
Get key takeaways from The Bio Report in a 5-minute read.
Save Hours Every Week
Stay current on your favorite podcasts without falling behind.
Frequently Asked Questions
What is Podzilla's The Bio Report daily summary?
It's a free AI-powered email that summarizes new episodes of The Bio Report as soon as they're published. You get the key takeaways, notable quotes, and links & mentions — all in a quick read.
How does the The Bio Report podcast summary work?
When a new episode drops, our AI transcribes and analyzes it, then generates a personalized summary tailored to your interests and profession. It's delivered to your inbox every morning.
Is this an official The Bio Report product?
No. Podzilla is an independent service that summarizes publicly available podcast content. We're not affiliated with or endorsed by Levine Media Group.
Can I get summaries of other podcasts too?
Absolutely! The free plan covers up to 3 podcasts, any in the catalog. Basic raises that to 15, Pro to 40 and Max to 100. Browse our full catalog at /podcasts.
How often does The Bio Report release new episodes?
The Bio Report publishes weekly. Our AI generates a summary within hours of each new episode.
What topics does The Bio Report cover?
The Bio Report covers topics including Science, Business, Medicine, Fitness, Health & Fitness, Life Sciences. Our AI identifies the specific themes in each episode and highlights what matters most to you.
Start getting The Bio Report summaries tomorrow morning.
Free forever for up to 3 podcasts. No credit card required.
Free forever for up to 3 podcasts. No credit card required.